

Human VEGF110 / VEGF-A Protein

Catalog Number: 29714-HNAH



Sino Biological
Biological Solution Specialist

General Information

Gene Name Synonym:

MVCD1; VEGF; VEGF165; VPF

Protein Construction:

A DNA sequence encoding the human VEGFA (NP_001191313.1) (Met1-Arg136) was expressed.

Source: Human

Expression Host: HEK293 Cells

QC Testing

Purity: > 95 % as determined by SDS-PAGE.

Bio-activity:

Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED₅₀ for this effect is 2-10ng/mL.

Endotoxin:

< 1.0 EU per µg protein as determined by the LAL method.

Stability:

Samples are stable for up to twelve months from date of receipt at -70 °C

Predicted N terminal: Ala 27

Molecular Mass:

The recombinant human VEGFA consists of 110 amino acids and predicts a molecular mass of 12.7 kDa.

Formulation:

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Storage:


Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:

Detailed reconstitution instructions are sent along with the products.

SDS-PAGE:



Protein Description

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.

References

1. Woolard J. *et al.* (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. *Cancer Res.* 64(21): 7822-7835.
2. Jia SF, *et al.* (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. *J Exp Ther Oncol.* 7(2): 89-97.
3. Cimpean AM, *et al.* (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. *Rom J Morphol Embryol.* 49(3): 303-8.

Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

For US Customer: Fax: 267-657-0217 • Tel: 215-583-7898

Global Customer: Fax :+86-10-5862-8288 • Tel:+86-400-890-9989 • <http://www.sinobiological.com>